Lumos Pharma, Inc. (LUMO)
Largest Insider Buys in Sector
LUMO Stock Price History Chart
LUMO Stock Performance
About Lumos Pharma, Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Insider Activity of Lumos Pharma, Inc.
Over the last 12 months, insiders at Lumos Pharma, Inc. have bought $0 and sold $0 worth of Lumos Pharma, Inc. stock.
On average, over the past 5 years, insiders at Lumos Pharma, Inc. have bought $1.01M and sold $1.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000 shares for transaction amount of $20,120 was made by McCracken Joseph S (director) on 2022‑11‑16.
List of Insider Buy and Sell Transactions, Lumos Pharma, Inc.
| 2023-08-02 | Sale | Chief Scientific Officer | 3,407 0.0418% | $3.21 | $10,919 | -8.84% | ||
| 2023-04-04 | Sale | Chief Scientific Officer | 2,214 0.027% | $3.27 | $7,240 | -3.74% | ||
| 2023-02-02 | Sale | Chief Scientific Officer | 439 0.0054% | $3.53 | $1,550 | -5.49% | ||
| 2022-11-16 | director | 4,000 0.0494% | $5.03 | $20,120 | -29.42% | |||
| 2022-09-23 | Chief Executive Officer | 208 0.0024% | $8.80 | $1,830 | -61.56% | |||
| 2022-09-21 | Chief Executive Officer | 2,214 0.0264% | $8.84 | $19,572 | -60.70% | |||
| 2022-09-20 | Chief Executive Officer | 1,506 0.0178% | $8.75 | $13,178 | -60.59% | |||
| 2022-09-19 | Chief Executive Officer | 541 0.0064% | $8.65 | $4,680 | -59.77% | |||
| 2021-09-08 | Sale | Chief Scientific Officer | 2,214 0.027% | $11.30 | $25,018 | -23.62% | ||
| 2021-09-08 | director | 10,000 0.121% | $11.21 | $112,116 | -23.62% | |||
| 2021-09-07 | director | 10,000 0.1194% | $11.11 | $111,139 | -23.97% | |||
| 2021-09-03 | director | 8,100 0.0969% | $11.35 | $91,905 | -25.37% | |||
| 2021-09-02 | director | 6,300 0.0745% | $11.23 | $70,739 | -25.35% | |||
| 2021-09-01 | director | 4,589 0.0546% | $10.87 | $49,892 | -22.19% | |||
| 2021-08-31 | director | 6,000 0.0708% | $10.70 | $64,181 | -21.61% | |||
| 2021-08-30 | director | 8,625 0.1023% | $10.52 | $90,738 | -19.60% | |||
| 2021-08-27 | director | 4,981 0.0595% | $10.50 | $52,282 | -18.73% | |||
| 2021-08-26 | director | 6,200 0.0736% | $10.07 | $62,430 | -15.76% | |||
| 2021-08-25 | director | 14,900 0.1769% | $9.87 | $147,078 | -14.07% | |||
| 2021-08-24 | director | 10,775 0.1275% | $9.45 | $101,871 | -10.41% |
Insider Historical Profitability
| Stine Seed Farm, Inc. | 10 percent owner | 7857732 96.722% | $4.33 | 3 | 0 | +18.87% |
| LALANDE KEVIN M. | director | 730446 8.9912% | $4.33 | 19 | 0 | <0.0001% |
| Link Charles J. Jr. | Chairman of the Board and CEO | 282756 3.4805% | $4.33 | 1 | 68 | <0.0001% |
| Lundquist David J. | director | 87630 1.0787% | $4.33 | 1 | 0 | +62.86% |
| HENNEMAN JOHN B III | EVP, Chief Financial Officer | 62316 0.7671% | $4.33 | 2 | 1 | +9.95% |
Institutional Investor Ownership
| Wells Fargo | $1.17M | 5.12 | 415,551 | -0.36% | -$4,230.00 | <0.0001 | |
| Goldman Sachs | $1.15M | 5.01 | 406,612 | 0% | +$2.82 | <0.0001 | |
| The Vanguard Group | $688,311.00 | 3.01 | 244,082 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $615,000.00 | 2.69 | 218,014 | -1.62% | -$10,155.31 | <0.01 | |
| Acuitas Investments, LLC | $396,743.00 | 1.73 | 140,689 | +12.3% | +$43,447.74 | 0.21 |